[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100374368":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":25,"centralContacts":33,"locations":41,"responsibleParty":57,"collaborators":59,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":7,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":7,"enrollmentInfo":76,"targetDuration":7,"studyType":79,"phases":7,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":44,"whyStopped":7,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",null,[9,13,16,19,22],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","Buccal swab","Pharmacogenetic panel testing is conducted by Stratipharm with the DNA of the buccal swab. TaqMan® polymerase chain reaction is proceeded to express the genetic information. Stratipharm is a product offered by Humatrix Aktiengesellschaft (AG). It consists of a laboratory analysis of approximately 100 pharmacological relevant genetic variations (polymorphisms) in over 30 different genes, which code for transport proteins, metabolizing enzymes, or drug targets.",{"type":10,"name":14,"description":15,"armGroupLabels":7,"otherNames":7},"EDTA Blood sample (4.9mL)","Genetic testing of potentially relevant genetic variants using the DNA extracted from the EDTA blood sample.",{"type":10,"name":17,"description":18,"armGroupLabels":7,"otherNames":7},"Serum sample (7.5mL)","blood sample to determine the actual levels of the compound in patients on medication assumed to be associated to an observed ADR (phenotype).",{"type":6,"name":20,"description":21,"armGroupLabels":7,"otherNames":7},"communication of test results","Certified study pharmacist evaluates and communicates clinically relevant test results to the subject and to the responsible physician",{"type":6,"name":23,"description":24,"armGroupLabels":7,"otherNames":7},"unstructured interview","One and six months after the communication of test results, the study center will make a phone call to the patient for an unstructured interview in order to gather information about potential outcomes",[26,30],{"name":27,"affiliation":28,"role":29},"Kurt Hersberger, Prof. Dr.","Pharmaceutical Care Research Group; Department of Pharmaceutical Sciences, University Basel","STUDY_CHAIR",{"name":31,"affiliation":28,"role":32},"Samuel Allemann, Prof. Dr.","PRINCIPAL_INVESTIGATOR",[34,38],{"name":31,"role":35,"phone":36,"phoneExt":7,"email":37},"CONTACT","+41 61 207 61 76","s.allemann@unibas.ch",{"name":27,"role":35,"phone":39,"phoneExt":7,"email":40},"+41 61 207 1971","kurt.hersberger@unibas.ch",[42],{"facility":43,"status":44,"city":45,"state":7,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Department of Pharmaceutical Sciences, University Basel","RECRUITING","Basel","4056","Switzerland","CH",{"type":50,"coordinates":51},"Point",[52,53],7.57327,47.55839,{"lat":53,"lon":52},[56],{"name":27,"role":35,"phone":39,"phoneExt":7,"email":40},{"type":58,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[60,63,65],{"name":61,"class":62},"Toppharm Apotheke Hersberger, Spalenberg 41, CH-4051 Basel","UNKNOWN",{"name":64,"class":62},"Universitätskinderspital Zürich, Lenggstrasse 30, 8008 Zürich",{"name":66,"class":62},"Institut für Spitalpharmazie, Solothurner Spitäler AG, Baslerstrasse 150, 4600 Olten","100374368","pharmacogenetic-testing-of-patients-with-unwanted-adverse-drug-reactions-or-therapy-failure-100374368",false,"NCT04154553","Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure","Inclusion Criteria:\n\n* New medication with known PGx association (preemptive)\n* Current medication with observation of adverse drug reactions probably linked to drugs with known PGx association (reactive)\n* Current medication with observation of therapy failure probably linked to drugs with known PGx association (reactive)\n* Current and\u002For new medication and a family history of adverse drug reactions\u002Ftherapy failure probably linked to drugs with known PGx association\n* Signed informed consent; for patients \\\u003C 14 years, the legal representative needs to sign the informed consent\n\nExclusion Criteria:\n\n* Insufficient German knowledge\n* Not able to personally visit to the study pharmacy",true,"ALL","2 Years",{"count":77,"type":78},400,"ESTIMATED","OBSERVATIONAL","Genetic makeup of a patient influences the efficacy and safety profile of a drug. This study is to summarize individual cases, where Pharmacogenetics (PGx) has been applied during pharmaceutical care. The primary objective is the compilation of case reports, where pharmacogenetic testing is applied to determine the hereditable component of the patient's susceptibility to experience therapy failure and\u002For adverse drug reactions. The experience with the compiled cases will be basis for the development of a reliable standard of procedure for pharmacogenetic testing in the community pharmacy. The cases will be supplemented with information on additional Parameters reported in the literature to affect efficacy or safety of the respective drug.",[82,83],"Adverse Drug Reaction","Therapy Failure",[85,86,87,88,89],"pharmacogenetics","single nucleotide polymorphism","absorption, distribution, metabolism and excretion (ADME)","genotyping","pharmacogenetic testing","2025-05-09",{"date":92,"type":93},"2025-05-14","ACTUAL",{"date":95,"type":93},"2019-10-15",{"date":97,"type":78},"2026-08",{"name":5,"class":6},1]